A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Conditions: Juvenile Psoriatic Arthritis Interventions: Drug: Adalimumab; Drug: Risankizumab Sponsors: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials